• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, December 11, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Oncotarget: 1B3 supports strong potential for therapeutic intervention in oncology

Bioengineer by Bioengineer
June 1, 2021
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

‘Despite decades of research and an unprecedented advancement of therapeutic options [1], cancer accounts for one in every six deaths worldwide, with ~18,000,000 new cases diagnosed in 2018 and expected to grow to ~30,000,000 by 2040’

IMAGE

Credit: Correspondence to – Michel Janicot – [email protected]

Oncotarget published “Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology” which reported that the authors comprehensively investigated miRNA-193a-3p’s mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic.

Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines.

1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration.

SiRNA silencing of 1B3 target mRNAs further highlighted the advantage of the pleiotropic mechanism of 1B3 action, as repression of individual targets did not achieve the same robust effect on cell proliferation in all cell lines.

Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer.

Dr. Michel Janicot from InteRNA Technologies BV said, “Despite decades of research and an unprecedented advancement of therapeutic options [1], cancer accounts for one in every six deaths worldwide, with ~18,000,000 new cases diagnosed in 2018 and expected to grow to ~30,000,000 by 2040”

“Despite decades of research and an unprecedented advancement of therapeutic options [1], cancer accounts for one in every six deaths worldwide, with ~18,000,000 new cases diagnosed in 2018 and expected to grow to ~30,000,000 by 2040”

Fittingly, miRNAs are commonly dysregulated in cancer, and can act as either tumor suppressor or oncogenic miRNA.

Antisense oligonucleotides against oncogenic miRNAs or synthetic copies of tumor suppressor miRNAs provide exciting novel approaches to cancer treatment.

As cancer is a multifactorial disease, this pleiotropic effect of miRNAs may be more effective at targeting different aspects of cancer cell biology.

Despite the significant literature on the role of miR-193a-3p in tumor development, and evidence that miR-193a-3p mimics reduce cancer growth, further studies with an efficient miR-193a-3p mimic delivery system are required to elucidate the possible use of miR-193a-3p mimics as a novel therapeutic intervention for cancer.

In addition, RNA-sequencing and subsequent pathway analysis in a panel of cell lines confirmed the multi-targeted nature of 1B3 by revealing hundreds of target genes with key roles in tumor cell survival, proliferation, and migration.

The Janicot Research Team concluded in their Oncotarget Research Output, “we have shown that the miR-193a-3p mimic, 1B3, consistently suppresses several pro-tumorigenic phenotypes in vitro. Some of these effects (e.g., viability) can be broadly applied to all cancer cell lines, while others (e.g., cell cycle arrest patterns) are unique to specific cell lines and genetic backgrounds. Using both individual and combined siRNA(s) we showed that no individual 1B3 target reproduced the miRNA effect which suggests that multiple, simultaneous, gene repression by 1B3 is more effective at reducing tumor cell growth than single gene targeting. These data add to the growing body of evidence that miR-193a-3p has an anti-cancer effect through several mechanisms, and that this overall anti-cancer effect is conserved regardless of tumor origin or genetic background. Finally, in two different in vivo models we showed a significant reduction of tumor growth. Together, this evidence supports the further clinical development of INT-1B3 as an anti-cancer therapeutic molecule.”

###

DOI – https://doi.org/10.18632/oncotarget.27894

Full text – https://www.oncotarget.com/article/27894/text/

Correspondence to – Michel Janicot – [email protected]

Keywords – miR-193a-3p, microRNA mimic, microRNA delivery in vivo, pleiotropic mechanism of microRNA

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget

Facebook – https://www.facebook.com/Oncotarget/

Twitter – https://twitter.com/oncotarget

LinkedIn – https://www.linkedin.com/company/oncotarget

Pinterest – https://www.pinterest.com/oncotarget/

Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

[email protected]

18009220957×105

Copyright © 2021 Impact Journals, LLC

Impact Journals is a registered trademark of Impact Journals, LLC

Media Contact
Ryan James Jessup
[email protected]

Original Source

https://www.oncotarget.com/news/pr/1b3-supports-strong-potential-for-therapeutic-intervention-in-oncology/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27894

Tags: Breast CancercancerCarcinogensMedicine/HealthProstate Cancer
Share12Tweet8Share2ShareShareShare2

Related Posts

Craig Portell, MD

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

December 11, 2023
Avik Chattopadhyay working in the lab

Boosting immunotherapy in non-responsive cancer cells

December 11, 2023

New way to force pathogenic proteins into degradation

December 11, 2023

Potential new treatment for pulmonary neuroendocrine tumors

December 11, 2023
Please login to join discussion

POPULAR NEWS

  • Figure 1

    Understanding rapid tendon regeneration in newts may one day help human athletes

    86 shares
    Share 34 Tweet 22
  • Photonic chip that ‘fits together like Lego’ opens door to semiconductor industry

    36 shares
    Share 14 Tweet 9
  • Study finds increasingly popular oral nicotine pouches do little to curb smokers’ cravings

    35 shares
    Share 14 Tweet 9
  • One of the largest magnetic storms in history quantified: Aurorae covered much of the night sky from the Tropics to the Polar Regions

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Diabetes: examining microvasculature with AI and an optoacoustic skin scanner

Bee species in Wake County, N.C.: are they missing or just hard to find?

In 7 months, online Target ID course from AI drug discovery company Insilico Medicine surpasses 2,500 users

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 58 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In